| Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome GF Watts, PHR Barrett, J Ji, AP Serone, DC Chan, KD Croft, F Loehrer, ... Diabetes 52 (3), 803-811, 2003 | 244 | 2003 |
| Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial EH De Boever, C Ashman, AP Cahn, NW Locantore, P Overend, ... Journal of Allergy and Clinical Immunology 133 (4), 989-996. e4, 2014 | 165 | 2014 |
| Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF … MC Holland, JU Wurthner, PJ Morley, MA Birchler, J Lambert, M Albayaty, ... Journal of clinical immunology 33, 1192-1203, 2013 | 82 | 2013 |
| Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury A Proudfoot, A Bayliffe, CM O’Kane, T Wright, A Serone, PJ Bareille, ... Thorax 73 (8), 723-730, 2018 | 74 | 2018 |
| High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics J Ji, GF Watts, AG Johnson, DC Chan, EMM Ooi, KA Rye, AP Serone, ... The Journal of Clinical Endocrinology & Metabolism 91 (3), 973-979, 2006 | 66 | 2006 |
| Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC‐0853, a selective reversible Bruton's tyrosine kinase inhibitor AE Herman, LW Chinn, SG Kotwal, ER Murray, R Zhao, M Florero, A Lin, ... Clinical Pharmacology & Therapeutics 103 (6), 1020-1028, 2018 | 62 | 2018 |
| A phase 1, randomized, placebo‐controlled, dose‐escalation study of an anti‐IL‐13 monoclonal antibody in healthy subjects and mild asthmatics P Hodsman, C Ashman, A Cahn, E De Boever, N Locantore, A Serone, ... British journal of clinical pharmacology 75 (1), 118-128, 2013 | 61 | 2013 |
| Role of N‐type calcium channels in autonomic neurotransmission in guineapig isolated left atria AP Serone, JA Angus British journal of pharmacology 127 (4), 927-934, 1999 | 25 | 1999 |
| EFFECT OF CYCLOSPORIN A ON NITRIC OXIDE PRODUCTION IN CULTURED LLC-PK1 CELLS R Lima, AP Serone, N Schor, EMS Higa Renal failure 23 (1), 43-52, 2001 | 24 | 2001 |
| Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea‐pig isolated left atria AP Serone, JA Angus British journal of pharmacology 127 (2), 383-390, 1999 | 19 | 1999 |
| OP18 Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: Results from the phase 2 DIVERGENCE 2 study W Reinisch, JF Colombel, GR D’Haens, J Rimola, A DeHaas-Amatsaleh, ... Journal of Crohn's and Colitis 16 (Supplement_1), i019-i021, 2022 | 15 | 2022 |
| Filgotinib for the treatment of small bowel Crohn’s disease: the DIVERGENCE 1 trial GR D’Haens, S Lee, SA Taylor, A Serone, J Rimola, JF Colombel, ... Gastroenterology 165 (1), 289-292. e3, 2023 | 10 | 2023 |
| Role of NPY Y1 receptors in cardiovascular control in the conscious rabbit AP Serone, CE Wright, JA Angus Journal of cardiovascular pharmacology 35 (2), 315-321, 2000 | 10 | 2000 |
| Heterogeneity of prejunctional NPY receptor‐mediated inhibition of cardiac neurotransmission AP Serone, CE Wright, JA Angus British journal of pharmacology 127 (1), 99-108, 1999 | 10 | 1999 |
| Exogenous NPY modulation of cardiac autonomic reflexes and its pressor effect in the conscious rabbit AP Serone, JA Angus, CE Wright British journal of pharmacology 123 (7), 1375-1384, 1998 | 9 | 1998 |
| Effects of JAK1-preferential inhibitor filgotinib on circulating biomarkers and whole blood genes/pathways of patients with moderately to severely active Crohn’s disease X Roblin, A Serone, OK Yoon, L Zhuo, E Grant, J Woo, J Liu, R Galien, ... Inflammatory Bowel Diseases 28 (8), 1207-1218, 2022 | 8 | 2022 |
| A novel TNFR1-targeting domain antibody attenuates pulmonary inflammation in a human model of lung injury, via actions on the lung micro-vascular endothelium AG Proudfoot, CM O'Kane, A Bayliffe, AP Serone, P Bareille, SP Smith, ... A47. Critical Illness: Novel Molecules and Models, A6589-A6589, 2014 | 8 | 2014 |
| P046 Histologic measures of mucosal healing correlate with endoscopic measures of disease activity at baseline and following induction therapy with the janus kinase 1 inhibitor … W Reinisch, G D’Haens, GD Hertogh, A Van der Aa, K Etchevers K, ... Inflammatory Bowel Diseases 24 (suppl_1), S16-S17, 2018 | 6 | 2018 |
| Baroreflex resetting but no vascular tolerance in response to transdermal glyceryl trinitrate in conscious rabbits AP Serone, JA Angus, CE Wright British journal of pharmacology 118 (1), 93-104, 1996 | 6 | 1996 |
| We-P11: 111 Lipid transfer proteins and apolipoprotein B-100 metabolism in the metabolic syndrome treated with fenofibrate J Ji, PHR Barrett, AG Johnson, DC Chan, AP Serone, KA Rye, GF Watts Atherosclerosis (Supplements)(Component) 3 (7), 370, 2006 | 4 | 2006 |
